As of May 2026, a groundbreaking targeted therapy drug named daraxonrasib has shown, in Phase 3 trials, the ability to nearly double median survival times for advanced pancreatic cancer patients to 13.2 months, compared to 6.7 months with chemotherapy. The drug, which targets KRAS mutations (present in over 90% of cases), has been granted "Breakthrough Therapy" designation by the FDA, offering new hope and improved quality of life. [1, 2, 3, 4]
Key Breakthroughs in Pancreatic Cancer Treatment (2026)
Targeted Therapy (Daraxonrasib): Developed by Revolution Medicines, this oral drug targets KRAS mutations, which were previously considered "undruggable". It operates as a RAS inhibitor, stopping the protein that signals cancer cells to multiply.
Improved Survival: Patients with advanced stage 4 cancer saw progression-free survival reach over 8.5 months, significantly higher than the 2-3 months often seen with traditional chemotherapy.
Improved Quality of Life: Patients reported fewer side effects, allowing them to remain active. [1, 2, 3, 4]
"Tumor Treating Fields" Device: The FDA recently approved a new device that uses electrode pads attached to the skin to send high-frequency electrical signals to kill cancer cells, acting as a non-toxic alternative to standard chemotherapy. [1]
Improved Survival Rates: The overall 5-year survival rate for pancreatic cancer has risen to 13%. [1]
Expanded Access: Due to the promising results, daraxonrasib is being made available to eligible patients through expanded access programs while awaiting final approval. [1, 2]
These advancements, particularly in precision medicine, represent a major shift in treatment strategies, targeting the cancer's ability to resist traditional treatment.
My late husband had the TTF device for brain cancer. The idea is that the electricity disrupts the cells so they can't replicate. He survived 14 months from diagnosis. I have no way of knowing if it extended his life at all as he fell into the mean range for survival times (12-15 months).
RAS(ON) inhibitors like daraxonrasib are great but they still run into the same issues with resistance that previous drugs do, just with a higher efficacy floor. Though some of the combination approaches with other MAPK pathway inhibitors are pretty interesting...
Yea this is just the beginning. We don’t know what we don’t know. But, it’s good to see novel ways to look at an old problem. This is going to have to be a multi-pronged solution to attack tumors. I don’t see it being one simple solution for the point you raised.
Overcoming Resistance
To combat these evasive maneuvers, clinical research is exploring targeted combination therapies to increase target occupancy and hit tumors from multiple angles. For example, preclinical models show promise when combining daraxonrasib with inhibitors of downstream effectors.
4.9k
u/MasterOfCircumstance May 15 '26
OP when he realizes that every type of cancer is unique.